Cargando…
Synergy of BID with doxorubicin in the killing of cancer cells
Overexpression of the BH3-interacting domain death agonist (BID) protein sensitizes certain cancer cell lines to apoptosis induced by anticancer agents, particularly by those acting through death receptors (e.g. TRAIL). Previously, we showed that recombinant BID fused with TAT cell penetrating pepti...
Autores principales: | ORZECHOWSKA, EMILIA JOANNA, GIRSTUN, AGNIESZKA, STARON, KRZYSZTOF, TRZCINSKA-DANIELEWICZ, JOANNA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391587/ https://www.ncbi.nlm.nih.gov/pubmed/25760094 http://dx.doi.org/10.3892/or.2015.3841 |
Ejemplares similares
-
Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis
por: Orzechowska, Emilia Joanna, et al.
Publicado: (2014) -
Dielectrophoresis-Based SERS Sensors for the Detection of Cancer Cells in Microfluidic Chips
por: Szymborski, Tomasz R., et al.
Publicado: (2022) -
Detection of Circulating Tumor Cells Using Membrane-Based SERS Platform: A New Diagnostic Approach for ‘Liquid Biopsy’
por: Kamińska, Agnieszka, et al.
Publicado: (2019) -
Effect of Varying Expression of EpCAM on the Efficiency of CTCs Detection by SERS-Based Immunomagnetic Optofluidic Device
por: Czaplicka, Marta, et al.
Publicado: (2020) -
Detection of circulating tumor cells in blood by shell-isolated nanoparticle – enhanced Raman spectroscopy (SHINERS) in microfluidic device
por: Niciński, K., et al.
Publicado: (2019)